LLY.SW
Eli Lilly and Company [LLY.SW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LLY.SW Stock Summary
Top 10 Correlated ETFs
LLY.SW
Top 10 Correlated Stocks
LLY.SW
In the News
LLY.SW Financial details
LLY.SW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 20.91 | 23.31 | 25.65 | 29.69 | 30.04 | |
| Net income per share | 3.14 | 4.84 | 6.47 | 5.85 | 6.57 | |
| Operating cash flow per share | 5.38 | 5.05 | 6.79 | 7.61 | 7.46 | |
| Free cash flow per share | 2.44 | 3.64 | 4.67 | 5.65 | 4.84 | |
| Cash per share | 7.21 | 2.55 | 3.85 | 4.1 | 2.33 | |
| Book value per share | 9.56 | 2.72 | 5.9 | 9.42 | 11.21 | |
| Tangible book value per share | 8.25 | -7.94 | -5.64 | -2.55 | -0.53 | |
| Share holders equity per share | 9.56 | 2.72 | 5.9 | 9.42 | 11.21 | |
| Interest debt per share | 10.29 | 16.92 | 17.72 | 18.06 | 17.44 | |
| Market cap | 116.36B | 110.56B | 159.34B | 242.14B | 357.68B | |
| Enterprise value | 119.34B | 124.03B | 172.28B | 255.21B | 371.85B | |
| P/E ratio | 36 | 23.84 | 25.73 | 43.38 | 57.28 | |
| Price to sales ratio | 5.41 | 4.95 | 6.49 | 8.55 | 12.53 | |
| POCF ratio | 21.06 | 22.86 | 24.52 | 33.35 | 50.49 | |
| PFCF ratio | 46.43 | 31.74 | 35.64 | 44.95 | 77.75 | |
| P/B Ratio | 11.84 | 42.41 | 28.24 | 26.97 | 33.59 | |
| PTB ratio | 11.84 | 42.41 | 28.24 | 26.97 | 33.59 | |
| EV to sales | 5.55 | 5.56 | 7.02 | 9.01 | 13.03 | |
| Enterprise value over EBITDA | 12.37 | 18.78 | 22.55 | 29.2 | 39.42 | |
| EV to operating cash flow | 21.6 | 25.64 | 26.51 | 35.15 | 52.49 | |
| EV to free cash flow | 47.61 | 35.61 | 38.54 | 47.37 | 80.83 | |
| Earnings yield | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | |
| Free cash flow yield | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Debt to equity | 1.05 | 6.06 | 2.94 | 1.88 | 1.52 | |
| Debt to assets | 0.23 | 0.4 | 0.36 | 0.35 | 0.33 | |
| Net debt to EBITDA | 0.31 | 2.04 | 1.69 | 1.5 | 1.5 | |
| Current ratio | 1.73 | 1.16 | 1.4 | 1.23 | 1.05 | |
| Interest coverage | 22.74 | 12.42 | 16.85 | 18.71 | 21.49 | |
| Income quality | 1.71 | 0.58 | 1.05 | 1.3 | 1.13 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 0.72 | 0.52 | 0.43 | 0.55 | 0.57 | |
| Sales general and administrative to revenue | 0.28 | 0.28 | 0.25 | 0.23 | 0.23 | |
| Research and developement to revenue | 0.24 | 0.25 | 0.25 | 0.25 | 0.25 | |
| Intangibles to total assets | 0.06 | 0.26 | 0.24 | 0.24 | 0.23 | |
| Capex to operating cash flow | -0.55 | -0.28 | -0.31 | -0.26 | -0.35 | |
| Capex to revenue | -0.14 | -0.06 | -0.08 | -0.07 | -0.09 | |
| Capex to depreciation | -1.88 | -1.1 | -1.53 | -1.21 | -1.63 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 26.01 | 17.23 | 29.31 | 35.21 | 40.71 | |
| ROIC | 0.26 | 0.23 | 0.23 | 0.22 | 0.24 | |
| Return on tangible assets | 0.08 | 0.16 | 0.17 | 0.15 | 0.16 | |
| Graham Net | -19.18 | -29.66 | -31.3 | -29.05 | -29.39 | |
| Working capital | 8.66B | 1.93B | 4.98B | 3.4B | 896.3M | |
| Tangible asset value | 8.47B | -7.6B | -5.39B | -2.43B | -504.2M | |
| Net current asset value | -12.45B | -22.88B | -23.35B | -21.2B | -20.68B | |
| Invested capital | 1.05 | 6.06 | 2.94 | 1.88 | 1.52 | |
| Average receivables | 5.52B | 5.66B | 6.24B | 7.53B | 8.34B | |
| Average payables | 1.31B | 1.31B | 1.51B | 1.64B | 1.8B | |
| Average inventory | 3.78B | 3.14B | 3.59B | 3.93B | 4.1B | |
| Days sales outstanding | 98.1 | 90.62 | 103.06 | 104.75 | 109.45 | |
| Days payables outstanding | 94.11 | 108.64 | 106.95 | 83.38 | 106.29 | |
| Days of inventory on hand | 241.54 | 246.68 | 264.95 | 193.96 | 237.27 | |
| Receivables turnover | 3.72 | 4.03 | 3.54 | 3.48 | 3.33 | |
| Payables turnover | 3.88 | 3.36 | 3.41 | 4.38 | 3.43 | |
| Inventory turnover | 1.51 | 1.48 | 1.38 | 1.88 | 1.54 | |
| ROE | 0.33 | 1.78 | 1.1 | 0.62 | 0.59 | |
| Capex per share | -2.94 | -1.41 | -2.12 | -1.96 | -2.61 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.21 | 7.71 | 7.68 | 7.33 | 9.24 | |
| Net income per share | 1.06 | 1.61 | 2.04 | 1.42 | 1.96 | |
| Operating cash flow per share | 0.91 | 2.43 | 1.66 | 1.82 | 0.7 | |
| Free cash flow per share | 0.41 | 1.74 | 1.08 | 0.87 | -0.23 | |
| Cash per share | 3.04 | 3.04 | 2.33 | 3.87 | 3.14 | |
| Book value per share | 9.49 | 11.18 | 11.21 | 11.79 | 12.3 | |
| Tangible book value per share | -3.03 | -0.94 | -0.53 | 0.14 | 0.19 | |
| Share holders equity per share | 9.49 | 11.18 | 11.21 | 11.79 | 12.3 | |
| Interest debt per share | 18.77 | 17.73 | 17.18 | 20 | 21.05 | |
| Market cap | 290.8B | 328.89B | 357.68B | 322.18B | 415.45B | |
| Enterprise value | 304.99B | 342.17B | 371.85B | 337.52B | 431.57B | |
| P/E ratio | 76.33 | 56.64 | 46.15 | 59.89 | 58.91 | |
| Price to sales ratio | 44.82 | 47.38 | 48.98 | 46.29 | 49.98 | |
| POCF ratio | 354.34 | 150.54 | 226.42 | 186.17 | 657.45 | |
| PFCF ratio | 786.59 | 210.21 | 349.26 | 389.53 | -2.03K | |
| P/B Ratio | 34.03 | 32.66 | 33.59 | 28.79 | 37.55 | |
| PTB ratio | 34.03 | 32.66 | 33.59 | 28.79 | 37.55 | |
| EV to sales | 47.01 | 49.29 | 50.93 | 48.49 | 51.92 | |
| Enterprise value over EBITDA | 146.61 | 142.44 | 155.4 | 198.07 | 186.03 | |
| EV to operating cash flow | 371.63 | 156.61 | 235.39 | 195.03 | 682.97 | |
| EV to free cash flow | 824.98 | 218.69 | 363.1 | 408.07 | -2.11K | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 1.97 | 1.58 | 1.52 | 1.69 | 1.7 | |
| Debt to assets | 0.36 | 0.33 | 0.33 | 0.36 | 0.34 | |
| Net debt to EBITDA | 6.82 | 5.52 | 5.92 | 9 | 6.95 | |
| Current ratio | 1.1 | 1.13 | 1.05 | 1.3 | 1.13 | |
| Interest coverage | 21.32 | 25.02 | 21.86 | 14.53 | 17.67 | |
| Income quality | 0.86 | 1.5 | 0.82 | 1.29 | 0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.93 | 0.61 | 0.46 | 0.76 | 0.58 | |
| Sales general and administrative to revenue | 0.24 | 0.22 | 0.23 | 0.25 | 0.23 | |
| Research and developement to revenue | 0.27 | 0.26 | 0.27 | 0.29 | 0.28 | |
| Intangibles to total assets | 0.24 | 0.23 | 0.23 | 0.21 | 0.2 | |
| Capex to operating cash flow | -0.55 | -0.28 | -0.35 | -0.52 | -1.32 | |
| Capex to revenue | -0.07 | -0.09 | -0.08 | -0.13 | -0.1 | |
| Capex to depreciation | -1.29 | -1.71 | -1.48 | -2.49 | -2.28 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Graham number | 15.03 | 20.14 | 22.68 | 19.39 | 23.29 | |
| ROIC | 0.06 | 0.07 | 0.06 | 0.04 | 0.06 | |
| Return on tangible assets | 0.03 | 0.04 | 0.05 | 0.03 | 0.04 | |
| Graham Net | -31.06 | -29.3 | -29.39 | -30.72 | -35.08 | |
| Working capital | 1.49B | 1.99B | 896.3M | 4.8B | 2.42B | |
| Tangible asset value | -2.73B | -849.8M | -504.2M | 134.7M | 166.9M | |
| Net current asset value | -21.29B | -19.66B | -20.68B | -21.06B | -22.33B | |
| Invested capital | 1.97 | 1.58 | 1.52 | 1.69 | 1.7 | |
| Average receivables | 7.74B | 8B | 8.44B | 8.79B | 9.1B | |
| Average payables | 1.55B | 1.67B | 1.81B | 1.97B | 2.25B | |
| Average inventory | 3.9B | 3.87B | 4.07B | 4.43B | 4.67B | |
| Days sales outstanding | 106.43 | 107.93 | 105.49 | 116.67 | 99.3 | |
| Days payables outstanding | 104.39 | 95.93 | 112.24 | 111.53 | 123.2 | |
| Days of inventory on hand | 245.33 | 218.35 | 250.55 | 251.45 | 238.95 | |
| Receivables turnover | 0.85 | 0.83 | 0.85 | 0.77 | 0.91 | |
| Payables turnover | 0.86 | 0.94 | 0.8 | 0.81 | 0.73 | |
| Inventory turnover | 0.37 | 0.41 | 0.36 | 0.36 | 0.38 | |
| ROE | 0.11 | 0.14 | 0.18 | 0.12 | 0.16 | |
| Capex per share | -0.5 | -0.69 | -0.58 | -0.95 | -0.93 |
LLY.SW Frequently Asked Questions
What is Eli Lilly and Company stock symbol ?
Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY.SW
What is Eli Lilly and Company stock quote today ?
Eli Lilly and Company stock price is $490 today.
Is Eli Lilly and Company stock public?
Yes, Eli Lilly and Company is a publicly traded company.
Company Profile
- Volume Average 59
- Market Capitalization 483.32B
- Employee 39K
- CEO Mr. David A. Ricks
- Headquarters Indianapolis,IN,US
- IPO Date 1998-07-17
-
Website
https://www.lilly.com 
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
